Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome — PCOS  

Polycystic Ovarian Syndrome Clinical Trial

Official title: Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome.

Status Terminated

Clinical Trial Summary

This study examines Raloxifene versus Clomiphene to induce ovulation in women with polycystic ovarian syndrome (PCOS).

Clinical Trial Description

Clomiphene citrate (CC) is the major pharmaceutical treatment of anovulation in polycystic ovary syndrome, used for over 40 years. Despite the vast experience using this drug, the pregnancy rates associated with its use are low and recent large studies from Australia regarding birth defects suggest that CC may be associated with birth defects. Alternatives to CC are limited. Another selective estrogen receptor modulator, Raloxifene (RAL) does not have the long half life exhibited by CC, and has recently been shown to be equivalent to CC in terms of ability to induce ovulation in PCOS women. In addition, prior studies have demonstrated potential benefits on markers of uterine receptivity in a cell line model by blocking estrogen activity. Beyond this, there are no studies to examine whether Raloxifene is an effective oral agent for the treatment of women desiring pregnancy, but the investigators' hypothesis is that Raloxifene will work as well as CC but be better at establishment and maintenance of pregnancy than CC ;

Related Conditions & MeSH terms

• Polycystic Ovarian Syndrome
• Polycystic Ovary Syndrome
• Syndrome

• NCT number: NCT01607320
• Study type: Interventional
• Source: Greenville Health System
• Status: Terminated
• Phase: N/A
• Start date: June 2012
• Completion date: March 2013